NEI
ADVM

Northwest & Ethical Investments’s Adverum Biotechnologies ADVM Stock Holding History

Northwest & Ethical Investments’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,390
Closed -$23.3K – 509
2024
Q2 		$23.3K Hold
3,390
– – ﹤0.01% 475
2024
Q1 		$47.9K Buy
+3,390
New +$51.6K ﹤0.01% 466

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Northwest & Ethical Investments's ADVM Position: Q3 2024 in Review

Northwest & Ethical Investments sold out of Adverum Biotechnologies (ADVM) in Q3 2024, closing a stake of 3,390 shares — an estimated $23.3K sold.

Northwest & Ethical Investments first reported a position in ADVM in Q1 2024 and held it in 2 quarters. The position peaked at $47.9K in Q1 2024. 77 funds tracked by Wall St. Rank hold ADVM as of Q3 2024.

  • Northwest & Ethical Investments reported no remaining Adverum Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Northwest & Ethical Investments sold 3,390 Adverum Biotechnologies shares in Q3 2024, an estimated $23.3K.
  • Northwest & Ethical Investments first reported a position in Adverum Biotechnologies in Q1 2024 and held it in 2 quarters.
  • Northwest & Ethical Investments's Adverum Biotechnologies position peaked at $47.9K in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2024.

Based on Northwest & Ethical Investments's 13F filing for Q3 2024, filed 14 Nov 2024.